IP Library Granted Patent US 8,658,215
Granted Patent B2
US 8,658,215 · App. 13/961,674 · Granted Feb 25, 2014

Injectable microspheres for dermal augmentation and tissue bulking

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,658,215
App. No.
13/961,674
Granted
Feb 25, 2014
Kind
B2
Abstract

The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions.

Claims (29)

1. A method for the treatment of urinary incontinence or urinary reflux disease, comprising

administering a composition as a tissue bulking agent to the urethra or bladder sphincter of a mammal, the composition comprising:

polymeric microspheres,

a polysaccharide, and

a biocompatible carrier,

wherein the microspheres comprise at least one of an acrylic polymer, an acrylamide polymer, an acrylate polymer, or mixtures thereof.

2. The method of claim 1 , wherein the method of treating urinary incontinence or urinary reflux disease comprises treating at least one of bladder-neck hypermobility, urethra hypermobility, intrinsic sphincter deficiency, or vesicoureteral reflux.

3. The method of claim 1 , wherein administering the composition comprises decreasing the internal lumen of the sphincter muscle via tissue bulking.

4. The method of claim 1 , wherein administering the composition comprises injecting the composition through a needle.

5. The method of claim 4 , wherein the needle is about 18 to about 26 gauge.

6. The method of claim 1 , wherein the polymeric microspheres are elastic, hydrophilic, non-toxic and substantially spherical.

7. The method of claim 1 , wherein the polymeric microspheres comprise at least one of hydroxymethyl methacrylate, diethylaminoethyl acrylamide, or N,N-methylene-bis-acrylamide.

8. The method of claim 1 , wherein the polymeric microspheres further comprise gelatin.

9. The method of claim 1 , wherein the polysaccharide comprises dextran.

10. The method of claim 1 , wherein the composition further comprises a therapeutic agent, drug, or a mixture thereof.

11. The method of claim 1 , wherein the composition is a suspension of the polymeric microspheres in the biocompatible carrier.

12. The method of claim 1 , wherein the polymeric microspheres are not capable of being digested or eliminated by the mammal's lymphatic system.

13. A kit for performing tissue bulking for the treatment of urinary incontinence or urinary reflux disease, comprising:

a) a needle for injecting a liquid based composition and configured for insertion via the urethra or bladder sphincter,

b) polymeric microspheres comprising at least one of an acrylic polymer, an acrylamide polymers, an acrylate polymer, or mixtures thereof,

c) a polysaccharide, and

d) a biocompatible carrier.

14. The kit of claim 13 , wherein the kit is configured for the treatment of at least one of bladder-neck hypermobility, urethra hypermobility, intrinsic sphincter deficiency, or vesicoureteral reflux.

15. The kit of claim 13 , wherein the needle is about 18 to 26 gauge.

16. The kit of claim 13 , wherein the microspheres are elastic, hydrophilic, non-toxic and substantially spherical.

17. The kit of claim 13 , wherein the polymeric microspheres comprise at least one of hydroxymethyl methacrylate, diethylaminoethyl acrylamide, or N,N-methylene-bis-acrylamide.

18. The kit of claim 13 , wherein the polysaccharide comprises dextran.

19. The kit of claim 13 , wherein the microspheres further comprise gelatin.

20. The kit of claim 13 , wherein the polymeric microspheres are not capable of being digested or eliminated by the mammal's lymphatic system.

Assignments (2)
SECURITY INTEREST Recorded Jul 30, 2018
From: BIOSPHERE MEDICAL, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 046502/0767 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2013
From: VOGEL, JEAN-MARIE; THOMAS, RICHARD; BOSCHETTI, EGISTO
To: BIOSPHERE MEDICAL, INC.
Reel/Frame 031414/0616 →